A Phase 2 interventional study of pemetrexed and cisplatin in Non-Small Cell Lung Cancer and Carcinoma, sponsored by Eli Lilly and Company. Completed at 3 sites in Poland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-21.
Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung — 22 open to participants now, 33 under way, 12 of them phase 3. Pemetrexed · Carcinoma, Non-Small-Cell Lung.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, this one is the 159th largest by enrollment of the 224 interventional ones that give a count, is one of 20 that started in 2005, is one of 128 in phase 2, and was the 13th registered.
7,638 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,840 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →22 of the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
Guangzhou Medical University · Sites in China
Ages 18–75
Second Affiliated Hospital of Nanchang University · Sites in China
Ages 18–85
Shanghai Chest Hospital · Sites in China
Ages 18+
Taipei Veterans General Hospital, Taiwan · Sites in Taiwan
Ages 20+
By country, each count listing its studies:
Pemetrexed: first FDA approval 2004 (ALIMTA), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →
Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 989 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
228 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 148 · Phase 3 48 · Phase 4 8
First in 2001; this study’s year is marked. 20 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 30 is below the median of 62 across 6,031 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 65 across the 224 interventional studies. Of the 161 that completed or were terminated, 89 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
76 of 228 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,111 studies on the registry; 154 are open to participants now.
Of its 541 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 124th largest by enrollment of the 139 interventional ones that give a count, is one of 10 that started in 2005, is one of 73 in phase 2, and was the 20th registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
7 of the studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 3 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04585490Phase 3Stanford UniversityAdaptive ctDNA-Based Personalization of Treatment During Consolidation Therapy in NSCLC | 2026-12 |
| NCT06417814Phase 3AstraZenecaA Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | 2027-01-11 |
| NCT03178552Phase 3Hoffmann-La RocheA Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | 2027-06-30 |
| NCT05805631Taipei Veterans General Hospital, TaiwanIntrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC | 2026-12-31 |
| NCT06440954Hunan Province Tumor HospitalEfficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases | 2026-12-31 |
Add all 7 to your calendar (.ics) → With an account.
Among the 228 studies testing pemetrexed in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study of pemetrexed combined with cisplatin used as neoadjuvant chemotherapy (2 or 3 cycles) in participants with operable non-small cell lung cancer (NSCLC) is to look at various genes present in participants' blood and tumor tissue to see if there is any link between the levels or changes in the genes and how participants with lung cancer respond to pemetrexed and cisplatin treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pemetrexed: 500 milligrams per square meter (mg/m\^2) intravenous (IV) every 21 days (q 21 days) for 3 cycles unless disease progression occurs Cisplatin: 75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
Drug: pemetrexed · Drug: cisplatin · Procedure: Radical Non-Small Cell Lung Cancer (NSCLC) surgery
500 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
Also known as: LY231514, Alimta
75 mg/m\^2 IV q 21 days for 3 cycles unless disease progression occurs
All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
High/Low Expression of Selected Molecular Markers in Tumor Tissues and Hypermethylated Genes in Peripheral Blood
Molecular markers assessed by immunohistochemistry: thymidylate synthase, glycinamide ribonucleotide formyl transferase (GARFT), epidermal growth factor receptor (EGFR); and by polymerase chain reaction: dihydrofolate reductase (DHFR), dihydropyrimidine dehydrogenase (DPD), folylpolyglutamate synthetase (FPGS), reduced folate carrier, alpha folate receptor, Excision Repair Cross-Complementation Group 1 (ERCC1), folylpolyglutamate hydrolase (FPGH). Hypermethylated genes assessed by methylation-specific polymerase chain reaction. Due to small sample size, tumor-tissue analyses were not done.
Time frame: Baseline, Cycle 2, and surgery (4-8 weeks after last dose of pemetrexed)
Percentage of Participants With Objective Tumor Response (Response Rate)
Tumor response to treatment using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Response rate was estimated as the total number of CR or PR, divided by the total number of participants treated.
Time frame: Treatment start to disease progression or surgery (4-8 weeks after last dose of pemetrexed)
Duration of Response
The duration of response was defined as the time from complete response (CR) or partial response (PR) to disease progression. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions.
Time frame: Time of response to disease progression (up to 44.4 months)
Disease Free Survival (DFS)
DFS was the time from date of first dose to first observation of progressive disease (PD) or death due to any cause. PD=20% increase in sum of longest diameter of target lesions. If a participant was not known to have died or have PD, DFS was censored at the date of the last objective progression-free disease assessment.
Time frame: Treatment start to disease progression or death from any cause (up to 45.5 months)
Overall Survival (OS)
OS was defined as the time from treatment start to death from any cause. For participants who were alive, OS was censored at the last contact date.
Time frame: Treatment start to death from any cause (up to 47.6 months)
| Milestone | Pemetrexed + Cisplatin |
|---|---|
| Started | 30 |
| Completed | 29 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
Molecular markers assessed by immunohistochemistry: thymidylate synthase, glycinamide ribonucleotide formyl transferase (GARFT), epidermal growth factor receptor (EGFR); and by polymerase chain reaction: dihydrofolate reductase (DHFR), dihydropyrimidine dehydrogenase (DPD), folylpolyglutamate synthetase (FPGS), reduced folate carrier, alpha folate receptor, Excision Repair Cross-Complementation Group 1 (ERCC1), folylpolyglutamate hydrolase (FPGH). Hypermethylated genes assessed by methylation-specific polymerase chain reaction. Due to small sample size, tumor-tissue analyses were not done.
No measurements were reported for this outcome.
Tumor response to treatment using Response Evaluation Criteria In Solid Tumors (RECIST) criteria. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions; Stable Disease (SD)=small changes that do not meet above criteria. Response rate was estimated as the total number of CR or PR, divided by the total number of participants treated.
| percentage of participants | Pemetrexed + Cisplatin |
|---|---|
| Percentage of Participants With Objective Tumor Response (Response Rate) | 34.5 (17.9 to 54.3) |
The duration of response was defined as the time from complete response (CR) or partial response (PR) to disease progression. Complete Response (CR)=disappearance of all target lesions; Partial Response (PR)=30% decrease in sum of longest diameter of target lesions; Progressive Disease (PD)=20% increase in sum of longest diameter of target lesions.
| months | Pemetrexed + Cisplatin |
|---|---|
| Duration of Response | 42.5 (8.31 to NA) |
DFS was the time from date of first dose to first observation of progressive disease (PD) or death due to any cause. PD=20% increase in sum of longest diameter of target lesions. If a participant was not known to have died or have PD, DFS was censored at the date of the last objective progression-free disease assessment.
| months | Pemetrexed + Cisplatin |
|---|---|
| Disease Free Survival (DFS) | 43.7 (25.36 to NA) |
OS was defined as the time from treatment start to death from any cause. For participants who were alive, OS was censored at the last contact date.
| months | Pemetrexed + Cisplatin |
|---|---|
| Overall Survival (OS) | NA (31.15 to NA) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pemetrexed + Cisplatin | — | 4/30 (13.3%) | 19/30 (63.3%) |
| Event | Pemetrexed + Cisplatin |
|---|---|
| Bronchopleural fistulaRespiratory, thoracic and mediastinal disorders | 2/30 |
| Gastric ulcerGastrointestinal disorders | 1/30 |
| Post procedural haemorrhageInjury, poisoning and procedural complications | 1/30 |
| Event | Pemetrexed + Cisplatin |
|---|---|
| Alanine aminotransferase increasedInvestigations | 4/30 |
| Aspartate aminotransferase increasedInvestigations | 4/30 |
| Weight increasedInvestigations | 4/30 |
| HyperkalaemiaMetabolism and nutrition disorders | 3/30 |
| HypernatraemiaMetabolism and nutrition disorders | 2/30 |
| RashSkin and subcutaneous tissue disorders | 2/30 |
| Age Continuous(years) | Pemetrexed + Cisplatin |
|---|---|
| Mean | 55.94 ± 8.214 |
| Sex: Female, Male(Participants) | Pemetrexed + Cisplatin |
|---|---|
| Female | 1 |
| Male | 29 |
| Race/Ethnicity, Customized(participants) | Pemetrexed + Cisplatin |
|---|---|
| Caucasian | 30 |
| Region of Enrollment(participants) | Pemetrexed + Cisplatin |
|---|---|
| Poland | 30 |
| Basis for Diagnosis(participants) | Pemetrexed + Cisplatin |
|---|---|
| Histopathological | 30 |
| Cytological | 0 |
| Initial Pathological Diagnosis(participants) | Pemetrexed + Cisplatin |
|---|---|
| Adenocarcinoma of Lung | 2 |
| Mixed Cell Carcinoma of Lung | 0 |
| Squamous Cell Carcinoma of Lung | 20 |
| Large Cell Carcinoma of Lung | 0 |
| Bronchoalveolar Carcinoma | 0 |
| Other | 8 |
| Stage of Disease at Study Entry(participants) | Pemetrexed + Cisplatin |
|---|---|
| Stage IB | 18 |
| Stage IIA | 2 |
| Stage IIB | 10 |
The record gives a start of May 2005, a primary completion of Jul 2008 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2010, 1 year 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pemetrexed · Cisplatin
Carcinoma, Non-Small-Cell Lung →